drugset
drugset / Trial / NCT07470840

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

NCT07470840 ↗

Phase 2 Not yet recruiting 27 enrolled Fujian Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.

Timeline

Start
2027-02-01
Primary completion
2029-02-01
Completion
2029-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemarituzumab Monoclonal antibody 1200 mg Intravenous
Subject Catequentinib Small molecule 12 mg Oral

Indications

renal cell adenocarcinoma